Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Astellas Pharma Inc.    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Tokyo Stock Exchange
11/30/2020 12/01/2020 12/02/2020 12/03/2020 12/04/2020 Date
1483.5 1501.5 1502 1510.5 1494.5 Last
18762100 9045400 8972300 6902100 7192000 Volume
-6.11% +1.21% +0.03% +0.57% -1.06% Change
Financials
Sales 2021 1 272 B 12 204 M 12 204 M
Net income 2021 190 B 1 820 M 1 820 M
Net cash position 2021 444 B 4 261 M 4 261 M
P/E ratio 2021 14,6x
Yield 2021 2,82%
Sales 2022 1 341 B 12 872 M 12 872 M
Net income 2022 229 B 2 202 M 2 202 M
Net cash position 2022 557 B 5 341 M 5 341 M
P/E ratio 2022 12,0x
Yield 2022 3,08%
Capitalization 2 776 B 26 642 M 26 641 M
EV / Sales 2021 1,83x
EV / Sales 2022 1,65x
Nbr of Employees 15 883
Free-Float 99,2%
More Financials
Company
Astellas Pharma Inc. specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders. Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%). 
Sector
Pharmaceuticals
Calendar
12/05Presentation
More about the company
Notations Surperformance© of Astellas Pharma Inc.
Trading Rating : Investor Rating :
More Ratings
All news about ASTELLAS PHARMA INC.
11/30Astellas Receives Approval of EVRENZO in Japan for the Treatment of Anemia of..
AQ
11/26ASTELLAS PHARMA : Launches a 'Contact for Potential Acquisition of ' R&D Program..
AQ
11/18Japan shares fall as virus surge, firmer yen weigh
RE
11/17ASTELLAS PHARMA : to Present New Data on Gilteritinib in FLT3 Mutation-Positive ..
AQ
11/09ASTELLAS PHARMA INC. : - XTANDI Approved by China NMPA for the Treatment of Non-..
AQ
11/02ASTELLAS PHARMA : Completes Acquisition of iota Biosciences
AQ
10/30Japan stocks fall, post biggest weekly loss in 3 months on virus worries
RE
10/29Japanese shares slump on virus worries, mixed earnings
RE
10/28ASTELLAS PHARMA : Receives U.S. FDA Fast Track Designation for ASP5354, an Inves..
AQ
10/27ASTELLAS PHARMA INC. : half-yearly earnings release
10/23ASTELLAS PHARMA : ITI Announces Promotion of Dr. Tim Coleman to SVP, Operations ..
AQ
10/21ASTELLAS PHARMA INC. : - U.S. FDA Grants Fast Track Designation for ASP0367/MA-0..
AQ
10/20ASTELLAS PHARMA INC. : - New Roxadustat Data in Anemia of Chronic Kidney Disease..
AQ
10/19ASTELLAS PHARMA : China Update – Drug Patents
AQ
10/16ASTELLAS PHARMA : to acquire iota Biosciences
AQ
More news
News in other languages on ASTELLAS PHARMA INC.
10/27ASTELLAS PHARMA INC. : Veröffentlichung des Halbjahresergebnisses
10/27ASTELLAS PHARMA INC. : publication des résultats semestriels
07/30ASTELLAS PHARMA INC. : publication des résultats trimestriels
07/30ASTELLAS PHARMA INC. : Veröffentlichung des Quartalsergebnisses
05/28Basileas klinische Studien liegen trotz Corona mehr oder weniger im Zeitplan
More news
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 2 275,00 JPY
Last Close Price 1 494,50 JPY
Spread / Highest target 114%
Spread / Average Target 52,2%
Spread / Lowest Target 10,4%
EPS Revisions
Managers
NameTitle
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Naoki Okamura Representative Director & Vice President
Tomokazu Fujisawa Director
Hiroko Sakai Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC.-20.08%27 024
JOHNSON & JOHNSON2.15%392 249
ROCHE HOLDING AG-4.55%287 762
PFIZER, INC.8.00%222 836
NOVARTIS AG-11.95%206 585
MERCK & CO., INC.-10.45%206 071